Advertisement

A Fungal Story

Fatal Forty DDI: fluconazole, phenytoin, CYP2C9, CYP2C19

Abstract

This cases discusses a pharmacokinetic interaction between phenytoin and fluconazole, resulting in phenytoin toxicity. Phenytoin is a cytochrome P450 2C9 and 2C19 substrate and fluconazole is a 2C9 and 2C19 inhibitor.

Keywords

Pharmacokinetic Inhibitor Inhibition Phenytoin Dilantin CYP2C9 CYP2C19 Antibiotics Fluconazole Toxicity CYP Cytochrome P450 2C9 2C19 

References

  1. 1.
    Niemi M, Backman JT, Neuvonen M, et al. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther. 2001;69(4):194–200.PubMedCrossRefGoogle Scholar
  2. 2.
    Mamiya K, Ieiri I, Shimamoto J, et al. The effects of genetic polymorphism of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia. 1998;39(12):1317–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Blum RA, Wilton JH, Hilligoss DM, et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther. 1991;49(4):420–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Cadle RM, Zenon 3rd GJ, Rodriguez-Barradas MC, et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother. 1994;28(2):191–5.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of PharmacyOregon Health and Science UniversityPortlandUSA
  2. 2.Department of Anesthesiology and Perioperative MedicineOregon Health and Science UniversityPortlandUSA

Personalised recommendations